IMVP-16 - AN EFFECTIVE REGIMEN FOR PATIENTS WITH LYMPHOMA WHO HAVE RELAPSED AFTER INITIAL COMBINATION CHEMOTHERAPY

Google Scholar
  • 1 January 1982
    • journal article
    • research article
    • Vol. 60  (3) , 693-697
Abstract
Results of 2nd-line chemotherapy regimens against lymphoma have usually been poor. A combination of ifosfamide, methotrexate and VP-16 (IMVP-16) was used to treat 52 patients with lymphoma who had relapsed or who had failed to attain a complete remission on front-line treatment. Thirty-two patients (62%) responded (CR [complete remission] 37%, PR [partial remission] 25%); 10 (19%) had a minor response. The median relapse-free interval of the responding patients was 12 mo.; the median survival of the whole group was 15 mo. Of the 18 patients who achieved CR, 10 still remain free of any evidence of disease. The factor that best predicted for response to IMVP-16 was the quality of the remission achieved on front-line therapy. In view of the poor prognosis associated with recurrent lymphoma, the results obtained are considered most encouraging. Patients with recurrent lymphoma can be successfully salvaged by the use of this combination regimen, especially if introduced early after relapse or preferably before progressive disease develops.